Entries by Trethera Support

Trethera Corporation announces appointment of Timothy “Tim” Donahue, M.D. to the Board of Directors 

Los Angeles, January 31, 2019 /PRNewswire/ — Trethera Corporation (Trethera), a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer, announced the nomination and acceptance of Timothy Donahue to Trethera’s Board of Directors by unanimous vote of the Board.  “I am delighted to have Dr. Donahue join the […]

Trethera Corporation and KYAN Therapeutics announce collaboration to develop artificial intelligence-driven optimization of solid cancer combination therapy

Los Angeles//Singapore, October 25, 2018 /PRNewswire/ —  Trethera Corporation (Trethera),a biopharmaceutical company committed to developing novel drugs targeting cellular nucleotide metabolism for the treatment of cancer,and KYAN Therapeutics, an artificial intelligence-based drug development firm, announced an agreement to collaborate on preclinical studies evaluating up to four different tumor types beginning this year leveraging their unique expertise to […]